Sign in
TerminatedPhase 2

Leucoselect Phytosome for Neoadjuvant Treatment of Early Stage Lung Cancer

Key facts

Who runs it
VA Office of Research and Development
Where
San Diego, United StatesSee the site
Trial code
Status
Terminated
Phase
Phase 2
People taking part
6 people enrolled
Started
20 Nov 2023
Ended
31 Mar 2025
Type of study
Interventional
Treatments tested
  • leucoselect phytosome
Record updated
17 February 2026
Why it stopped
Early termination by sponsor due to substantial delays with subjects recruitment

Who can take part

Age
21 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Initial screening:
  • Lesions suspicious for lung cancer
  • Competent to provide consent
  • CBC within normal limits (WNL)
  • liver function test WNL
  • Normal Creatinine clearance as measured by the Cockcroft-Gault equation
  • ECOG Performance status: 0-1
  • Enrollment for treatment with LP:
  • Histologically proven and surgically resectable clinical I and II stage NSCLC

Who cannot take part

  • Other concurrent malignancy, excluding non-melanoma type skin cancer
  • Have had a solid organ or bone marrow transplant
  • Systemic corticoid steroid therapy of > 10 mg prednisone equivalent daily
  • Concurrent use of Grapes or related products
  • Pts receiving medications known to be modulators of cytochrome P450 3A4 if alternative medication cannot be provided
  • Currently taking other investigational agents
  • Pts with concurrent medical conditions that may interfere with completion of tests, therapy, or the follow up schedule
  • Inability to provide informed consent (e.g. cognitive impairment, severe psychiatric disorders)
  • Hypersensitivity to grapes or related products
  • Advance respiratory disease (Post resection FEV1 < 0.8 liters, resting hypoxemia, to ensure pts have adequate reserve to undergo diagnostic procedures and surgical resection)
  • Unstable angina
  • Coagulopathy (PT-INR > 1.2, PTT > 40 seconds) or history of bleeding/clotting problems
  • Pregnancy
  • Breast feeding
  • Unwilling to refrain from drinking more than 1 glass of wine a day

Where in United States

  • VA San Diego Healthcare System, San Diego, CASan Diego, United States

About the trial

What the trial wants to find out

Lung cancer is the leading cause of cancer death in the country, surpassing deaths caused by colorectal, prostate and breast cancers combined. Veterans are at higher risk of lung cancer due to the higher rate of smoking and environmental toxin exposures. The lack of effective therapy for lung cancer provides the impetus to search for alternative, safe, and effective treatment agents to improve treatment strategy against lung cancer, enhance the probability of a cure and reduce recurrence. Based on encouraging preclinical and clinical findings from an early phase I lung cancer prevention study, using a special formulation of a standardized grape seed extract with enhanced absorption called leucoselect phytosome (LP), the purpose of this new CSR\&D Merit Review project is to evaluate the potential usefulness of LP for pre-surgical treatment of early stage lung cancer patients in a phase IIa clinical trial. Findings from this study may set the stage for larger, confirmatory trials in the near future.

The group in the trial

  • InterventionTreatment being tested

    All qualified participants meeting entry criteria that are enrolled will receive 2-3 weeks of oral LP treatment.

    Treatment: leucoselect phytosome

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
17 February 2026